Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial

American Heart Journal

Volumn 151, Issue 1, 2006, Pages 92-99

  Serebruany, Victor L ^a   Pokov, Alex N ^a   Malinin, Alex I ^a   O'Connor, Christopher ^b   Bhatt, Deepak L ^c   Tanguay, Jean Francois ^d   Sane, David C ^e   Hennekens, Charles H ^f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e WAKE FOREST UNIVERSITY   (United States)

^f UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CD40 LIGAND; CD51 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PADGEM PROTEIN; VALSARTAN; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; CENTRIFUGAL ANALYZER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG INHIBITION; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; SEVERITY OF ILLNESS INDEX; TETRAZOLES; VALINE;

EID: 29144470389     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.03.001     Document Type: Article

References (38)

1. C.H. Hennekens Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors Circulation 97 1998 1095 1102
2. M. Ezzati How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART Lancet 364 2004 912 914
3. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 289 2003 2560 2572
4. W.C. Cushman The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression J Clin Hypertens 5 3 Suppl 2 2003 14 22
5. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol Lancet 359 2002 995 1003
6. H. Lithell, L. Hansson, and I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
7. Val-HeFT (Valsartan Heart Failure Trial), J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
8. S. Yusuf, M.A. Pfeffer, and Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
9. H.H. Parving, H. Lehnert, and J. Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
10. B.M. Brenner, M.E. Cooper, and D. de Zeeuw The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) J Renin Angiotensin Aldosterone Syst 1 2000 328 335
11. S. Nadar, and G.Y. Lip The prothrombotic state in hypertension and the effects of antihypertensive treatment Curr Pharm Des 9 2003 1715 1732
12. M.J. Siebers, and T.L. Goodfriend Platelet angiotensin receptors in young and old humans J Gerontol 41 1986 574 578
13. M. Pawlak, and G. Macdonald Platelet angiotensin II receptors in pregnancy Clin Sci (Lond) 83 1992 737
14. S.W. Graves, T.J. Moore, and E.W. Seely Increased platelet angiotensin II receptor number in pregnancy-induced hypertension Hypertension 20 1992 627 632
15. P.N. Baker, F. Broughton Pipkin, and E.M. Symonds Platelet angiotensin II binding sites in hypertension in pregnancy Lancet 2 1989 1151
16. 1-receptor subtype Br J Pharmacol 110 1993 761 771
17. V.L. Serebruany, A.I. Malinin, and D.R. Lowry Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events J Cardiovasc Pharmacol 43 2004 677 684
18. 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release Hypertension 40 2002 521 527
19. Z.M. Ruggeri New insights into the mechanisms of platelet adhesion and aggregation Semin Hematol 31 1994 229 239
20. E.F. Mammen, P.C. Comp, and R. Gosselin PFA-100 system: a new method for assessment of platelet dysfunction Semin Thromb Hemost 24 1998 195 202
21. K.A. Ault Flow cytometric measurement of platelet function and reticulated platelets Ann N Y Acad Sci 677 1993 293 308
22. V.L. Serebruany, and P.A. Gurbel The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GP IIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost 81 1999 314 316
23. H. Suzuki, H. Shibata, and M. Murakami Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leukocytes Endocr J 42 1995 15 22
24. H. Shibata, H. Suzuki, and M. Murakami Angiotensin II type 1 receptor messenger RNA levels in human blood cells of patients with primary and secondary hypertension: reference to renin profile J Hypertens 12 1994 1275 1284
25. 2+ concentrations in essential hypertension Hypertension 22 1993 853 862
26. C. Ferri, C. De Angelis, and M.A. Del Porto Blood platelets and angiotensin II: angiotensin II release after platelet aggregation J Hypertens 6 Suppl 1988 S69 S71
27. P.T. Larsson, J.H. Schwieler, and N.H. Wallen Platelet activation during angiotensin II infusion in healthy volunteers Blood Coagul Fibrinolysis 11 2000 61 69
28. E.C. Liu, A. Hedberg, and H.J. Goldenberg DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors Prostaglandins 44 1992 89 99
29. J.I. Guerra-Cuesta, M. Monton, and J.A. Rodriguez-Feo Effect of losartan on human platelet activation J Hypertens 17 1999 447 452
30. A.M. Jimenez, M. Monton, and R. Garcia Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan J Cardiovasc Pharmacol 37 2001 406 412
31. P. Li, M. Fukuhara, and D.I. Diz Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation J Pharmacol Exp Ther 292 2000 238 246
32. A. Lopez-Farre, and L. Sanchez de Miguel Angiotensin II AT(1) receptor antagonists and platelet activation Nephrol Dial Transplant 16 Suppl 1 2001 S45 S49
33. M. Monton, A. Jimenez, and A. Nunez Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation J Cardiovasc Pharmacol 35 2000 906 913
34. M.W. Radomski, and S. Moncada Regulation of vascular homeostasis by nitric oxide Thromb Haemost 70 1993 36 41
35. D.R. Riddell, and J.S. Owen Nitric oxide and platelet aggregation Vitam Horm 57 1999 25 48
36. A. Schafer, D. Fraccarollo, and S. Hildemann Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition Thromb Haemost 89 2003 1024 1030
37. I.F. Islim, D. Bareford, and D.G. Beevers A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension Platelets 12 2001 274 278
38. K. Yasunari, K. Maeda, and T. Watanabe Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy J Am Coll Cardiol 43 2004 2116 2123